"Harringtonines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tetracyclic spiro-BENZAZEPINES isolated from the seeds of CEPHALOTAXUS. They are esters of the alkaloid cephalotaxine and may be effective as antineoplastic agents.
| Descriptor ID |
D006248
|
| MeSH Number(s) |
D03.132.420 D03.633.100.079.533 D03.633.400.624
|
| Concept/Terms |
Harringtonines- Harringtonines
- Cephalotaxine Alkaloids
- Alkaloids, Cephalotaxine
- Cephalotaxus Alkaloids
- Alkaloids, Cephalotaxus
|
Below are MeSH descriptors whose meaning is more general than "Harringtonines".
Below are MeSH descriptors whose meaning is more specific than "Harringtonines".
This graph shows the total number of publications written about "Harringtonines" by people in this website by year, and whether "Harringtonines" was a major or minor topic of these publications.
![]()
To see the data from this visualization as text,
click here.
Below are the most recent publications written about "Harringtonines" by people in Profiles.
-
Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia. Leuk Lymphoma. 2017 09; 58(9):1-6.
-
Prediction of response and survival in patients with chronic-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate: logistic regression and landmark analyses. Blood Cancer J. 2015 Dec 11; 5:e376.
-
The hypomethylating agent decitabine prior to chemotherapy improves the therapy efficacy in refractory/relapsed acute myeloid leukemia patients. Oncotarget. 2015 Oct 20; 6(32):33612-22.
-
Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate. Leuk Lymphoma. 2016; 57(3):654-65.
-
Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up. Cancer. 2015 May 15; 121(10):1637-44.
-
Effectiveness of homoharringtonine (omacetaxine mepesuccinate) for treatment of acute myeloid leukemia: a meta-analysis of Chinese studies. Clin Lymphoma Myeloma Leuk. 2015 Jan; 15(1):13-21.
-
Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemia. Clin Cancer Res. 2014 Apr 01; 20(7):1735-40.
-
Omacetaxine mepesuccinate (synribo) - newly launched in chronic myeloid leukemia. Expert Opin Pharmacother. 2013 Oct; 14(14):1977-86.
-
Homoharringtonine/omacetaxine mepesuccinate: the long and winding road to food and drug administration approval. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):530-3.
-
Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):584-91.